Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Percentage of personnel spending as a proportion of biosimilar review costs dropped more than 17% over three-year period as equipment and other spending more than doubled.
You may also be interested in...
Absence of any fee increases reflects growing numbers of both approved biosimilars and products under development, as well as agency’s commitment to start spending down some of the carryover balance from prior years’ fee collections.
For the first time since the biosimilar user fee program began, FDA spent more in fees than it collected, and more than it spent in appropriated funds.